New prostate cancer treatment available at Edinburgh Cancer Centre is first in Scotland
Men in the South East of Scotland may now be able to access a new treatment for prostate cancer, which is available at the Edinburgh Cancer Centre, Western General Hospital.
The Edinburgh Cancer Centre (ECC) is the first in Scotland to offer High–dose-rate brachytherapy (HDR-BT) for treatment of prostate cancer.
It was successfully introduced by NHS Lothian earlier this year and is now being made available to suitable patients across the South East of Scotland.
Prostate cancer is the most common cancer among Scottish males affecting 1 in 10 men. With more than 3,000 men diagnosed every year this figure is only expected to increase.
But, with early detection and improved treatments, survival rates are also increasing. Radiotherapy is commonly used to cure prostate cancers and increasing the radiation dose in treatments has shown to improve long-term cancer control.
The HDR-BT service at the ECC offers an additional treatment approach to deal with aggressive but localised prostate cancer. It allows a higher dose of radiation to be targeted directly into the prostate gland in a safe and controlled way. This minimises radiation exposure to surrounding normal tissue and thereby reduces potential side effects.
The new treatment is being offered alongside existing radiotherapy treatments at the Edinburgh Cancer Centre, expanding the range of treatment options on offer.
Dr Aravindhan Sundaramurthy, Consultant Clinical Oncologist at the Edinburgh Cancer Centre explains: “We have been successfully delivering low-dose-rate brachytherapy (LDR-BT) for prostate cancer with over 1000 men throughout Scotland benefitting from the service. However, men with more advanced or aggressive disease would not be eligible for LDR-BT on its own.”
“The start of the new HDR-BT service opens a very important therapeutic option for men with high-risk prostate cancer features. It brings together the skills and expertise of staff across our radiotherapy, oncology and anaesthetic teams to deliver another treatment option.”
He said: “I would strongly encourage anyone who is offered this treatment to go for it. It was a very smooth process and the care I received from the NHS was absolutely first class. I was looked after every step of the way and I knew that I was in the best possible hands for my treatment.”
This HDR-BT service is a collaborative effort involving radiotherapy nursing, prostate clinical oncologists, anaesthetics, therapeutic radiographers and oncology physicists. It is currently being offered at the Edinburgh Cancer Centre for suitable patients within the South-east Scotland Cancer Network with an aim to expand the service to other patients across Scotland.
Anyone looking for more information about prostate cancer including details of common symptoms and testing can visit NHS Inform: www.nhsinform.scot/illnesses-and-conditions/cancer/cancer-types-in-adults/prostate-cancer
23
0
20
